Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Profit After Tax (2019 - 2026)

InMed Pharmaceuticals has reported Profit After Tax over the past 5 years, most recently at -$2.0 million for Q4 2025.

  • For Q4 2025, Profit After Tax rose 21.23% year-over-year to -$2.0 million; the TTM value through Dec 2025 reached -$7.7 million, up 2.97%, while the annual FY2025 figure was -$8.2 million, 6.49% down from the prior year.
  • Profit After Tax for Q4 2025 was -$2.0 million at InMed Pharmaceuticals, down from -$1.7 million in the prior quarter.
  • Over five years, Profit After Tax peaked at -$347622.0 in Q2 2023 and troughed at -$7.9 million in Q2 2022.
  • A 5-year average of -$2.6 million and a median of -$2.1 million in 2022 define the central range for Profit After Tax.
  • Biggest five-year swings in Profit After Tax: skyrocketed 95.58% in 2023 and later tumbled 464.44% in 2024.
  • Year by year, Profit After Tax stood at -$4.3 million in 2021, then skyrocketed by 50.94% to -$2.1 million in 2022, then rose by 29.65% to -$1.5 million in 2023, then crashed by 74.2% to -$2.6 million in 2024, then increased by 21.23% to -$2.0 million in 2025.
  • Business Quant data shows Profit After Tax for INM at -$2.0 million in Q4 2025, -$1.7 million in Q3 2025, and -$1.8 million in Q2 2025.